FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2938876444> ?p ?o ?g. }

• W2938876444 endingPage "86" @default.
• W2938876444 startingPage "78" @default.
• W2938876444 abstract "IntroductionThymic carcinoma (TC) is a rare cancer with a poor prognosis and limited treatment options, especially after relapse.MethodsIn this open-label, two-stage, multicentre, single-arm and phase II trial, the main eligibility criteria were unresectable or recurrent TC, an Eastern Cooperative Oncology Group–performance status of 0 or 1, progression after at least one chemo(radio)therapy and no history of autoimmune disease. Nivolumab was administered at a dose of 3 mg/kg every 2 weeks. The primary end-point was response rate (RR) as evaluated by central review using Response Evaluation Criteria In Solid Tumours (RECIST), version 1.1. The planned sample size was 15 for each stage, with a threshold RR of 5%, an expected RR of 20%, one-sided alpha of 5% and power of 80%.ResultsBetween July 1 and August 16 2016, 15 patients were accrued in the first stage. Response was assessable in all patients, and 13 had squamous histology. Median follow-up time was 14.1 months (range: 2.4–17.5). The median number of nivolumab received was eight (range: 3–33). RR was 0% (95% confidential interval [CI]: 0–21.8). Eleven patients had stable disease (SD) including five patients with SD for 24 or more weeks. Median progression-free survival was 3.8 months (95% CI: 1.9–7.0). Two patients experienced immune-related serious adverse events (grade III aspartate aminotransferase (AST) increase and grade II adrenal insufficiency). Because the early termination criteria (less than one responder) were fulfilled during the first stage, the patient accrual was terminated.ConclusionsDespite the small number of patients, nivolumab was unable to produce tumour shrinkage by RECIST in previously treated unresectable or recurrent TC." @default.
• W2938876444 created "2019-04-25" @default.
• W2938876444 creator A5005598571 @default.
• W2938876444 creator A5025249611 @default.
• W2938876444 creator A5034276209 @default.
• W2938876444 creator A5039645415 @default.
• W2938876444 creator A5039879533 @default.
• W2938876444 creator A5054884728 @default.
• W2938876444 creator A5067259938 @default.
• W2938876444 creator A5069589468 @default.
• W2938876444 creator A5070493419 @default.
• W2938876444 creator A5074862416 @default.
• W2938876444 creator A5078287634 @default.
• W2938876444 creator A5086229141 @default.
• W2938876444 creator A5090846902 @default.
• W2938876444 date "2019-05-01" @default.
• W2938876444 modified "2023-10-16" @default.
• W2938876444 title "Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study" @default.
• W2938876444 cites W1767875808 @default.
• W2938876444 cites W2009392040 @default.
• W2938876444 cites W2012510274 @default.
• W2938876444 cites W2019607817 @default.
• W2938876444 cites W2029883618 @default.
• W2938876444 cites W2034339271 @default.
• W2938876444 cites W2042515268 @default.
• W2938876444 cites W2057195209 @default.
• W2938876444 cites W2071071105 @default.
• W2938876444 cites W2090914388 @default.
• W2938876444 cites W2125257681 @default.
• W2938876444 cites W2139863684 @default.
• W2938876444 cites W2166624818 @default.
• W2938876444 cites W2168558240 @default.
• W2938876444 cites W2193769500 @default.
• W2938876444 cites W2239425853 @default.
• W2938876444 cites W2525217971 @default.
• W2938876444 cites W2606601794 @default.
• W2938876444 cites W2784751095 @default.
• W2938876444 cites W2792006020 @default.
• W2938876444 cites W4246097753 @default.
• W2938876444 doi "https://doi.org/10.1016/j.ejca.2019.03.012" @default.
• W2938876444 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30991261" @default.
• W2938876444 hasPublicationYear "2019" @default.
• W2938876444 type Work @default.
• W2938876444 sameAs 2938876444 @default.
• W2938876444 citedByCount "85" @default.
• W2938876444 countsByYear W29388764442019 @default.
• W2938876444 countsByYear W29388764442020 @default.
• W2938876444 countsByYear W29388764442021 @default.
• W2938876444 countsByYear W29388764442022 @default.
• W2938876444 countsByYear W29388764442023 @default.
• W2938876444 crossrefType "journal-article" @default.
• W2938876444 hasAuthorship W2938876444A5005598571 @default.
• W2938876444 hasAuthorship W2938876444A5025249611 @default.
• W2938876444 hasAuthorship W2938876444A5034276209 @default.
• W2938876444 hasAuthorship W2938876444A5039645415 @default.
• W2938876444 hasAuthorship W2938876444A5039879533 @default.
• W2938876444 hasAuthorship W2938876444A5054884728 @default.
• W2938876444 hasAuthorship W2938876444A5067259938 @default.
• W2938876444 hasAuthorship W2938876444A5069589468 @default.
• W2938876444 hasAuthorship W2938876444A5070493419 @default.
• W2938876444 hasAuthorship W2938876444A5074862416 @default.
• W2938876444 hasAuthorship W2938876444A5078287634 @default.
• W2938876444 hasAuthorship W2938876444A5086229141 @default.
• W2938876444 hasAuthorship W2938876444A5090846902 @default.
• W2938876444 hasBestOaLocation W29388764441 @default.
• W2938876444 hasConcept C121608353 @default.
• W2938876444 hasConcept C126322002 @default.
• W2938876444 hasConcept C141071460 @default.
• W2938876444 hasConcept C146357865 @default.
• W2938876444 hasConcept C151730666 @default.
• W2938876444 hasConcept C168563851 @default.
• W2938876444 hasConcept C197934379 @default.
• W2938876444 hasConcept C203092338 @default.
• W2938876444 hasConcept C2777701055 @default.
• W2938876444 hasConcept C2779984678 @default.
• W2938876444 hasConcept C2780030458 @default.
• W2938876444 hasConcept C31760486 @default.
• W2938876444 hasConcept C535046627 @default.
• W2938876444 hasConcept C71924100 @default.
• W2938876444 hasConcept C86803240 @default.
• W2938876444 hasConcept C90924648 @default.
• W2938876444 hasConceptScore W2938876444C121608353 @default.
• W2938876444 hasConceptScore W2938876444C126322002 @default.
• W2938876444 hasConceptScore W2938876444C141071460 @default.
• W2938876444 hasConceptScore W2938876444C146357865 @default.
• W2938876444 hasConceptScore W2938876444C151730666 @default.
• W2938876444 hasConceptScore W2938876444C168563851 @default.
• W2938876444 hasConceptScore W2938876444C197934379 @default.
• W2938876444 hasConceptScore W2938876444C203092338 @default.
• W2938876444 hasConceptScore W2938876444C2777701055 @default.
• W2938876444 hasConceptScore W2938876444C2779984678 @default.
• W2938876444 hasConceptScore W2938876444C2780030458 @default.
• W2938876444 hasConceptScore W2938876444C31760486 @default.
• W2938876444 hasConceptScore W2938876444C535046627 @default.
• W2938876444 hasConceptScore W2938876444C71924100 @default.
• W2938876444 hasConceptScore W2938876444C86803240 @default.
• W2938876444 hasConceptScore W2938876444C90924648 @default.
• W2938876444 hasFunder F4320311405 @default.

• next